At the heart of London’s pharmaceutical industry, AstraZeneca, the UK’s largest drugmaker, is reportedly in advanced talks to acquire Bristol Myers Squibb, its American counterpart, in a deal that could reshape the global drug industry.
If a merger is finalized, the combined company would hold a valuation close to $400bn, becoming one of the largest pharmaceutical deals ever seen and the fourth-largest drugmaker by market value.
Bristol Myers Squibb, or BMS, is best known for its groundbreaking cancer treatments and has a significant UK presence, including research operations in Moreton on the Wirral and administrative offices in Uxbridge. AstraZeneca, based in Cambridge, has a market value of nearly £196bn.
The potential deal was first flagged by the Financial Times and has sent ripples through both British and US financial circles. If successful, it would significantly boost AstraZeneca’s US footprint, where it is already investing $50bn in research and manufacturing by 2030. AstraZeneca was itself forged from the 1999 merger of Swedish firm Astra AB and the UK’s Zeneca Group.
Pascal Soriot, the company’s long-standing CEO, has been instrumental in steering AstraZeneca through major challenges, including a near-takeover by Pfizer in 2014, which valued the firm at £70bn, and the $39bn (£29bn) purchase of Alexion in 2021.
Despite setbacks, like the recent failure of its heart drug Wainua, AstraZeneca remains confident about hitting its 2030 growth targets, aiming for $80bn in annual sales by that year. Bristol Myers Squibb has also been on an upward trajectory, reporting second-quarter revenues of $12.97bn, up 5% year-on-year, and raising its 2026 growth outlook.
Though discussions have been ongoing for months, a deal is far from certain. AstraZeneca has not yet issued a comment, and BMS has not publicly responded.
AstraZeneca reported $14.1 billion in first-half cancer-drug revenue, driven by blockbuster medicines including Tagrisso, Calquence, Imfinzi, Enhertu, and Datroway. Calquence surpassed $1 billion in quarterly sales for the first time, while Imfinzi and Imjudo revenue surged by 25%. AstraZeneca also highlighted positive Phase 3 data across bladder and gastric cancer, reinforcing AstraZeneca's stance that combining immunotherapy with ADCs could become a long-term growth driver.
Meanwhile, Bristol Myers pointed to Opdivo, Breyanzi, its expanding hematology portfolio, and its ADC pipeline as pillars of growth. It also announced another Phase 3 lung-cancer study and said recent data boosted confidence in its ADC platform.